anti-CD19 DASH CAR-T / Hrain Biotech - LARVOL DELTA

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • IL15 • IL6

Preclinical study of DASH CAR-T cells manufactured in 48 hours (ESMO 2022) - "Strikingly, 4 out 5 mice treated with one million anti-CD19 DASH CAR-T cells survived beyond 60 days. In contrast, 1 or 2 out of 5 mice treated with one million or 5 million anti-CD19 CAR-T cells survived. Conclusions DASH CAR-T cells manufactured in two days expanded significantly better in vivo and more effective than conventional CAR-T cells. Clinical trials are planned to use DASH CAR-T platform to rapidly generate CAR-T cells to treat patients with ALL or r/r B-ALL."

CAR T-Cell Therapy • IO biomarker • Preclinical • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCR7 • PTPRC